Danish pharmaceutical company expands its capacity with a new laboratory in Kőbánya

Danish pharmaceutical company expands its capacity with a new laboratory in Kőbánya

The foundation stone of the new building of Xellia Pharmaceuticals has been placed at the Kőbánya-based premises of the Danish pharmaceutical company. The facility to be built in the framework of a development worth USD 10 million will contain advanced microbiological and chemical analytical laboratories and offices. The goal of the expansion is to ensure that a high-level product stability and pre-market testing can be carried out in the framework of centralised laboratory services.

With its more than 100 years of experience, the Copenhagen-based Xellia Pharmaceuticals which specialises in the production of pharmaceutical products for the treatment of serious and life-threatening infections is a leading developer, manufacturer and supplier in the pharmaceutical industry. In more than 70 countries, the company has relations with approximately 500 partners in the healthcare sector. At present, the company employs nearly 1,200 people in its operation and production units located in Denmark, Hungary, the United States and China.

The new, approximately 3,000 m2 facility will be built beside the Xellia production plant which currently employs 200 people and produces pharmaceutical ingredients. The multi-storey building that will be completed by the summer of 2017 will have modern microbiological and chemical analysis laboratories and offices. The building which provides space for centralised laboratory services will play an important role in Xellia's global operating strategy by strengthening the pre-release and the stability testing capacity of pharmaceutical products produced in the company's other international factories. The company plans to expand its excellent professional team in the manufacturing, product testing and quality assurance field with 80 people.